Therapeutic Applications of Curcumin Nanomedicine Formulations in Cardiovascular Diseases

Journal of Clinical Medicine

卷:9

Miquel Martorell¹  Gitishree Das¹  Gerardo Leyva-Gómez²  MaríaL. Del Prado-Audelo²  Zorica Stojanović-Radić³  WilliamC. Cho⁴  YengkhomDisco Singh⁵  Marzieh Sharifi-Rad⁶  Hernán Cortés⁷  Javad Sharifi-Rad⁸  Natália Martins⁹  JayantaKumar Patra⁹  Bahare Salehi¹⁰ 

[1] Medical Converged Science, Dongguk University-Seoul, Goyangsi 10326, Korea;

[2] Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Circuito Exterior S/N, Del. Coyoacán, Mexico City 04510, Mexico;

[3] Department of Biology and Ecology, Faculty of Science and Mathematics, University of Niš, 18000 Niš, Serbia;

[4] Department of Nutrition and Dietetics, Faculty of Pharmacy, University of Concepcion, Concepcion 4070386, Chile;

[5] Department of Post-Harvest Technology, College of Horticulture and Forestry, Central Agricultural University, Pasighat 791102, Arunachal Pradesh, India;

[6] Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal;

[7] Laboratorio de Medicina Genómica, Departamento de Genética, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City 14389, Mexico;

[8] Research Department of Agronomy and Plant Breeding, Agricultural Research Institute, University of Zabol, Zabol 3585698613, Iran;

[9] Research Institute of Biotechnology &

[10] Student Research Committee, School of Medicine, Bam University of Medical Sciences, Bam 44340847, Iran;

关键词: curcumin;    cardiovascular disease;    nanomedicine;    nanocurcumin;    liposome;    nanoformulation;   

DOI  :  10.3390/jcm9030746

来源: DOAJ

【 摘 要 】

Cardiovascular diseases (CVD) compromises a group of heart and blood vessels disorders with high impact on human health and wellbeing. Curcumin (CUR) have demonstrated beneficial effects on these group of diseases that represent a global burden with a prevalence that continues increasing progressively. Pre- and clinical studies have demonstrated the CUR effects in CVD through its anti-hypercholesterolemic and anti-atherosclerotic effects and its protective properties against cardiac ischemia and reperfusion. However, the CUR therapeutic limitation is its bioavailability. New CUR nanomedicine formulations are developed to solve this problem. The present article aims to discuss different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in CVD treatment, with an emphasis on their formulation properties, experimental evidence, bioactivity, as well as challenges and opportunities in developing these systems.

【 授权许可】

Unknown